Optimization of novel combi-molecules: identification of balanced and mixed bcr-abl/DNA targeting properties.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2007-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BMCL.2007.05.067PMID 17572088
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Combi-Targeting Concept: In vitro and In vivo Fragmentation of a Stable Combi-Nitrosourea Engineered to Interact with the Epidermal Growth Factor Receptor while Remaining DNA Reactive

  2007cited by this paper
• Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05

  2007cited by this paper
• A general strategy for creating "inactive-conformation" abl inhibitors.

  2006cited by this paper
• Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.

  2006cited by this paper
• The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).

  2006cited by this paper
• Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl.

  2005cited by this paper
• Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias.

  2005cited by this paper
• Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase.

  2003cited by this paper
• Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.

  2003cited by this paper
• Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept.

  2003cited by this paper
• Inhibition of Epidermal Growth Factor Receptor-Mediated Signaling by “Combi-Triazene” BJ2000, a New Probe for Combi-Targeting Postulates

  2002cited by this paper
• The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties

  2002cited by this paper
• Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41

  2002cited by this paper
• BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance.

  2001cited by this paper
• Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

  2001cited by this paper
• The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.

  1999cited by this paper
• MMFF VI. MMFF94s option for energy minimization studies

  1999cited by this paper
• Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway

  1997cited by this paper
• Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives

  1997cited by this paper
• Triazene metabolism. V. Chemical and biological properties of N,N-bis-[(1-aryl-3-methyltriazen-3-yl)-methyl]-methylamines: potential prodrugs for the cytotoxic monomethyltriazenes.

  1985cited by this paper
• Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: potential prodrugs for the active metabolites of the anti-tumour triazene, DTIC.

  1985cited by this paper
• Synthesis of Potential Anticancer Agents. XII. Nitrogen Mustards from p-Aminobenzoic Acid Derivatives1,2

  1961cited by this paper

• Linear triazenes: Versatile scaffolds for chemical biology and drug design.

  2025cites this paper
• Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent

  2020cites this paper
• The potential of combi-molecules with DNA-damaging function as anticancer agents.

  2017cites this paper
• Trajectories for women who disclose intimate partner violence in health care settings: the key role of abuse severity

  2016cites this paper
• Analysis of surface area features of structurally diverse molecules for Bcr/Abl kinase inhibitory activity and antiproliferative activity

  2014cites this paper
• Advances in the development of hybrid anticancer drugs

  2013cites this paper
• Rationally designed multitarget anticancer agents.

  2013cites this paper
• 18 Targeting AMPK for Therapeutic Intervention in Type 2 Diabetes

  2012cites this paper
• Targeting AMPK for Therapeutic Intervention in Type 2 Diabetes

  2011cites this paper
• ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro

  2011cites this paper
• [Strategy of molecular drug design: dual-target drug design].

  2009cites this paper
• Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia

  2008cites this paper